Cells in the human body communicate their health status to the immune system by degrading cellular proteins and presenting fragments of each on the cell surface in association class I MHC proteins. Appropriately educated, cytotoxic T-lymphocytes (CTL) (CD8+ T-cells) bind to the class I MHC molecules on the cell surface, sample the peptides being presented and kill those cells that express new peptides as a result of viral, bacterial and parasitic infection, tissue transplantation and cellular transformation (cancer). Presently, the most effective treatment for late stage metastatic melanoma involves adoptive cell therapy (ACT) with CD8+ T-cells. In this approach, tumor-infiltrating lymphocytes (TIL) are isolated from surgically removed tumor, expanded ex vivo and then re-introduced to the patient after ablation of his or her immune system by a combination of chemotherapy and total body irradiation. Efforts to improve this technology are in progress and involve transfecting patient CD8+ T-cells (prior to expansion) with high affinity receptors for specific tumor associated class I MHC peptides. With this additional step, it should be possible to use ACT to treat any human tumor. What is lacking are MHC class I peptides that are;(a) differentially displayed on cancer vs normal cells, (b) shared by large cohorts of patients with the same cancer (c) shared by multiple tumor types, (d) derived from proteins whose genes cannot be mutated or deleted without compromising tumor survival, and (e) not available for display on MHC molecules in the thymus or lymph nodes to trigger deletion of reactive CD8+ T-cells. Proposed here is research to develop new mass spectrometry instrumentation and methods for the identification of class I MHC phosphopeptides that are derived from dysregulated signal transduction pathways associated with cellular transformation characteristic of cancer cells and thus satisfy the above criteria. This research should make it possible to extend adoptive T-cell therapy to a number of other cancers including acute myeloid leukemia, chronic lymphocytic leukemia, pancreatic-,colorectal- and heptocellullar- adenocarcinoma and renal cancer.
PUBLIC HEALTHE RELEVANCE: Proposed here is research to develop new mass spectrometry instrumentation and methods for the identification of class I MHC phosphopeptides that are derived from dysregulated signal transduction pathways associated with cellular transformation. This research should make it possible to extend adoptive Tcell therapy beyond melanoma to other cancers including acute myeloid leukemia, chronic lymphocytic leukemia, pancreatic-, colorectal-, and heptocellullar adenocarcinoma and renal cancer.
|Cobbold, Mark; De La Pena, Hugo; Norris, Andrew et al. (2013) MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 5:203ra125|
|Earley, Lee; Anderson, Lissa C; Bai, Dina L et al. (2013) Front-end electron transfer dissociation: a new ionization source. Anal Chem 85:8385-90|
|Chen, Shuming; Li, Yili; Depontieu, Florence R et al. (2013) Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity. J Immunol 191:5097-106|
|Compton, Philip D; Strukl, Joseph V; Bai, Dina L et al. (2012) Optimization of electron transfer dissociation via informed selection of reagents and operating parameters. Anal Chem 84:1781-5|
|Brims, Daniel R; Qian, Jie; Jarchum, Irene et al. (2010) Predominant occupation of the class I MHC molecule H-2Kwm7 with a single self-peptide suggests a mechanism for its diabetes-protective effect. Int Immunol 22:191-203|
|Li, Yili; Depontieu, Florence R; Sidney, John et al. (2010) Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells. J Mol Biol 399:596-603|
|Depontieu, Florence R; Qian, Jie; Zarling, Angela L et al. (2009) Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A 106:12073-8|
|Mohammed, Fiyaz; Cobbold, Mark; Zarling, Angela L et al. (2008) Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat Immunol 9:1236-43|
|Altrich-VanLith, Michelle L; Ostankovitch, Marina; Polefrone, Joy M et al. (2006) Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J Immunol 177:5440-50|
|Coon, Joshua J; Syka, John E P; Shabanowitz, Jeffrey et al. (2005) Tandem mass spectrometry for peptide and protein sequence analysis. Biotechniques 38:519, 521, 523|
Showing the most recent 10 out of 39 publications